Spencer Feldman

Articles

Enfortumab Vedotin Shows Manageable Safety in Older Patients With Urothelial Carcinoma

March 24th 2025

Enfortumab vedotin demonstrated a manageable safety profile and no unexpected toxicities in patients aged 80 years and older with urothelial carcinoma.

Retrospective Data Show Potential Safety of Enfortumab Vedotin in Older Patients With Urothelial Carcinoma

March 2nd 2025

A retrospective study revealed that enfortumab vedotin did not produce excessive toxicity in older patients with urothelial carcinoma.

Aspirin Is Associated With Reduced Recurrence Risk in PI3K+ CRC

January 25th 2025

Aspirin reduced the risk of disease recurrence in colorectal cancer harboring PI3K pathway alterations.

Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer

December 16th 2024

Ultra-sensitive tissue-free ctDNA testing showed that baseline ctDNA was associated with larger pathological tumor size in HR-positive breast cancer.

Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer

December 15th 2024

Elacestrant increased real-world TTNT for patients with ESR1-mutant HR-positive/HER2-negative breast cancer vs PFS from the phase 3 EMERALD trial.

ICIs Result in Increased Rates of High-Grade irAEs for Older Patients With Breast Cancer

December 14th 2024

The risk of developing high-grade immune-related AEs was heightened among patients with breast cancer who were older and who had chronic kidney disease.

Recurrence-Free Interval Is Longer With Low ctDNA Levels at Baseline in TNBC

December 13th 2024

ctDNA was most frequently detected within 6 months post-treatment in patients with TNBC, aligning with the early recurrence pattern characteristic of the disease.

100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis

December 13th 2024

Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.

BGB-16673 Demonstrates Initial Antitumor Activity, Tolerability in Select Relapsed/Refractory B-Cell Malignancies

December 10th 2024

BGB-16673 monotherapy showed early activity and a tolerable safety profile in relapsed/refractory Waldenström macroglobulinemia, CLL, and SLL.

Olverembatinib May Be Effective in Second Line for CP-CML

December 8th 2024

Olverembatinib showed potential in patients with chronic-phase chronic myeloid leukemia with prior exposure to first-line second-generation TKIs.

Relatlimab Plus Nivolumab and Chemo Improves Clinical Benefit in Stage IV NSCLC

September 14th 2024

Findings from the phase 2 RELATIVITY-104 study demonstrates a clinical benefit with the addition of relatlimab to nivolumab and chemotherapy.

Low-Dose Pembrolizumab May Prove Equal Efficacy as a Standard Dose for Stage IV NSCLC

September 14th 2024

A lower dose of pembrolizumab may be as effective as the standard dose for treating stage IV non-small cell lung cancer.

Longer Follow-Up Confirms Superior Outcomes With Amivantamab Plus Chemo in EGFR-Mutant Advanced NSCLC

September 14th 2024

Amivantamab plus chemotherapy yielded promising OS trends compared with chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib.

x